ARCHIVES

FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

Letter To the Editor: Screening Revisited

May 20, 1994

NCS Group Asks DRG Adjustments For Institutions With Peer reviewed Components, 25 Protocol Patients

July 1, 1983

On More Victory For Sol Garb: FDA Approves THC

June 14, 1985

Abstracts From AACR Annual Meeting

May 21, 1976

NCAB Gives Life To Three CBCCP Contractors Marked For Termination; Compromise “Reasonable” – DeVita

May 30, 1980